Northwest Investment Counselors LLC Makes New $103,000 Investment in Pfizer Inc. (NYSE:PFE)

Northwest Investment Counselors LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,556 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Los Angeles Capital Management LLC boosted its stake in Pfizer by 59.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 47,663 shares of the biopharmaceutical company’s stock worth $1,323,000 after purchasing an additional 17,799 shares in the last quarter. Global Assets Advisory LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $725,000. Capital Advisors Wealth Management LLC purchased a new position in Pfizer in the 1st quarter worth approximately $202,000. Annex Advisory Services LLC lifted its position in Pfizer by 29.8% in the 1st quarter. Annex Advisory Services LLC now owns 11,005 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 2,528 shares in the last quarter. Finally, Fermata Advisors LLC boosted its stake in Pfizer by 42.5% during the 1st quarter. Fermata Advisors LLC now owns 11,348 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 3,384 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $33.91.

Pfizer Trading Down 1.0 %

Shares of Pfizer stock opened at $28.93 on Tuesday. The company has a fifty day moving average of $29.07 and a 200 day moving average of $28.47. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a market capitalization of $163.93 billion, a P/E ratio of -482.17, a P/E/G ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the firm posted $0.67 EPS. The company’s revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.